ImmuPharma (LON:IMM) Stock Price Up 28.8% - Here's What Happened

Key Points

• ImmuPharma's stock price surged 28.8% during trading, closing at GBX 13.98 ($0.19) after a previous close of GBX 10.85 ($0.15).
• Trading volume increased dramatically, with approximately 44.7 million shares exchanged, marking a 451% rise from the average daily trading volume.
• The company reported a negative earnings per share (EPS) of GBX (0.38) in its last quarterly results, with analysts forecasting a significantly negative EPS for the current fiscal year.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was up 28.8% during trading on Saturday . The stock traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). Approximately 44,749,293 shares traded hands during trading, an increase of 451% from the average daily volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Trading Up 28.8%

The company has a 50 day simple moving average of GBX 3.12 and a 200-day simple moving average of GBX 2.93. The stock has a market cap of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.